98%
921
2 minutes
20
In 1920, John B. Watson and Rosalie Rayner attempted to condition a phobia in a young infant named "Albert B." In 2009, Beck, Levinson, and Irons proposed that Little Albert, as he is now known, was actually an infant named Douglas Merritte. More recently, Fridlund, Beck, Goldie, and Irons (2012) claimed that Little Albert (Douglas) was neurologically impaired at the time of the experiment. They also alleged that Watson, in a severe breach of ethics, probably knew of Little Albert's condition when selecting him for the study and then fraudulently hid this fact in his published accounts of the case. In this article, we present the discovery of another individual, Albert Barger, who appears to match the characteristics of Little Albert better than Douglas Merritte does. We examine the evidence for Albert Barger as having been Little Albert and, where relevant, contrast it with the evidence for Douglas Merritte. As for the allegations of fraudulent activity by Watson, we offer comments at the end of this article. We also present evidence concerning whether Little Albert (Albert Barger) grew up with the fear of furry animals, as Watson and Rayner speculated he might.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/a0036854 | DOI Listing |
Geroscience
April 2025
Department of Psychology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
Machine learning (ML) on structural MRI data shows high potential for classifying Alzheimer's disease (AD) progression, but the specific contribution of brain regions, demographics, and proteinopathy remains unclear. Using Alzheimer's Disease Neuroimaging Initiative (ADNI) data, we applied an extreme gradient-boosting algorithm and SHAP (SHapley Additive exPlanations) values to classify cognitively normal (CN) older adults, those with mild cognitive impairment (MCI) and AD dementia patients. Features included structural MRI, CSF status, demographics, and genetic data.
View Article and Find Full Text PDFJ Neurol Neurosurg Psychiatry
March 2025
Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Psychiatric University Hospital, Zurich, Switzerland
Background And Objectives: Neuropsychiatric symptoms (NPS) are common in older people with cognitive impairment and Alzheimer's disease (AD). No biomarkers to detect the related pathology or predict the clinical evolution of NPS are available yet. This study aimed to identify plasma proteins that may serve as biomarkers for NPS and NPS-related clinical disease progression.
View Article and Find Full Text PDFBrain
August 2024
UK Dementia Research Institute, University College London, London, WC1E 6BT, UK.
Alzheimer's disease typically progresses in stages, which have been defined by the presence of disease-specific biomarkers: amyloid (A), tau (T) and neurodegeneration (N). This progression of biomarkers has been condensed into the ATN framework, in which each of the biomarkers can be either positive (+) or negative (-). Over the past decades, genome-wide association studies have implicated ∼90 different loci involved with the development of late-onset Alzheimer's disease.
View Article and Find Full Text PDFCurr Dev Nutr
February 2022
Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
Background: Parental involvement has been shown to favorably affect childhood weight-management interventions, but whether these interventions influence parental diet and cardiometabolic health outcomes is unclear.
Objectives: The aim was to evaluate whether a 1-y family-based childhood weight-management intervention altered parental nutrient biomarker concentrations and cardiometabolic risk factors (CMRFs).
Methods: Secondary analysis from a randomized-controlled, parallel-arm clinical trial (NCT00851201).
Nat Ecol Evol
September 2021
Ecology and Evolutionary Biology, University of Colorado Boulder, Boulder, CO, USA.